GlassScriptPhysician profile
Devon Douglas Moser
NPI 1063912202
$10,989.00
in general payments reported to CMS, 2019-2025
32 companies · $3,264 in 2025
The $3,264 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,129 · 2022: $1,453 · 2023: $2,910 · 2024: $2,233 · 2025: $3,264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,345 · Education: $34.00 · Consulting Fee: $28.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,345.15 |
| Education | $34.00 |
| Consulting Fee | $28.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,751.61 | 2021-2025 | Tezspire, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,429.09 | 2021-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Grifols USA, LLC | $1,415.37 | 2021-2025 | Prolastin-C Liquid, Xembify |
| Regeneron Healthcare Solutions, INC. | $971.74 | 2021-2025 | Dupixent |
| Csl Behring | $737.52 | 2021-2025 | Hizentra, Andembry, Haegarda |
| Genzyme Corporation | $533.38 | 2021-2025 | |
| Blueprint Medicines Corporation | $475.42 | 2023-2025 | Ayvakit |
| Genentech USA, INC. | $382.76 | 2022-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $282.56 | 2021-2025 | Cuvitru, Takhzyro, Hyqvia |
| Novartis Pharmaceuticals Corporation | $235.39 | 2024-2025 | |
| Biocryst US Sales Co., LLC | $179.42 | 2021-2023 | Orladeyo |
| Ars Pharmaceuticals Operations, INC. | $176.00 | 2025 | Neffy |
| Amgen INC. | $149.03 | 2022-2025 | Tezspire |
| Leo Pharma INC. | $147.50 | 2023-2025 | Adbry |
| Optinose US, INC. | $146.64 | 2021-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $144.09 | 2022-2025 | Opzelura, Opzelura |
| Phathom Pharmaceuticals, INC. | $141.62 | 2024-2025 | Voquezna |
| Kaleo, INC. | $135.78 | 2021-2023 | Auvi-Q |
| Pfizer INC. | $88.13 | 2021-2025 | |
| Organon LLC | $83.92 | 2025 | Vtama |
| Pharming Healthcare, INC. | $61.70 | 2024-2025 | Ruconest |
| Teva Pharmaceuticals USA, INC. | $46.73 | 2021 | |
| Adma Biomanufacturing LLC | $45.92 | 2022-2023 | |
| Abbvie INC. | $43.54 | 2022 | |
| Galderma Laboratories, L.P. | $36.28 | 2024-2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.02 | 2022 | |
| Verona Pharma, INC. | $24.94 | 2025 | Ohtuvayre |
| Ionis Pharmaceuticals, INC. | $22.21 | 2025 | Dawnzera |
| Cycle Pharmaceuticals INC | $20.24 | 2024 | Sajazir |
| Mylan Specialty L.P. | $17.85 | 2022 | |
| Alk-Abello, INC | $16.02 | 2023 | Timothy, Standardized, Standardized Mite D. Farinae, Alternaria Tenuis |
| Merck Sharp & Dohme LLC | $14.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devon Moser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.